Innate leukocytes manifest dynamic and distinct inflammatory responses upon challenges with rising dosages of pathogen associated molecular pattern molecules (PAMPs) such as lipopolysaccharide (LPS). To differentiate signal strengths, innate leukocytes may utilize distinct intra-cellular signaling circuitries modulated by adaptor molecules. Toll-interacting protein (Tollip) is one of the critical adaptor molecules in Toll-like receptor 4 (TLR4) signaling and potentially playing key roles in modulating the dynamic adaptation of innate leukocytes to varying dosages of external stimulants. While Tollip may serve as a negative regulator of NFkB signaling pathway in cells challenged with higher dosages of LPS, it acts as a positive regulator for low-grade chronic inflammation in leukocytes programmed by subclinical low-dosages of LPS. We aim to show recent progress in our understanding of complex innate leukocyte dynamics and its relevance in the pathogenesis of resolving versus non-resolving chronic inflammatory diseases. / Ph. D. / White blood cells, or leukocytes, have a dynamic inflammatory response to rising doses of bacterial cell wall components. Lipopolysaccharide (LPS) is a ubiquitous component of gram negative bacteria that is recognized by Toll-like receptor 4 (TLR4) and can shed into the blood stream, causing low-grade non-resolving inflammation. In order to differentiate between varying signal strengths of LPS, leukocytes utilize signaling within the cell, which is often regulated by adaptor molecules. Toll-interacting protein (Tollip) is one of the critical adaptor molecules in TLR4 signaling and potentially plays key roles in modulating the dynamic adaptation of innate leukocytes to varying dosages of external stimulants. While Tollip serves to inhibit the pro-inflammatory NFκB signaling in cells challenged with higher dosages of LPS, it acts to increase low-grade chronic inflammation in leukocytes programmed by low-dosages of LPS. In these studies we show recent progress in elucidating the mechanism for Tollip involvement in low-grade non-resolving inflammation in mouse fibroblast cells.

Introdução- Considerando o papel da glutamina como substrato energético para os enterácitos e como fornecedora de nitrogênio para o músculo esquelético, o estudo hipotetiza que a suplementação com glutamina pode contribuir na modulação da inflamação sistêmica e na preservação da massa muscular de idosos. Objetivos-avaliar os efeitos da suplementação com glutamina em alguns marcadores de inflamação e de composição corporal de idosos em risco de fragilidade. Métodos-estudo randomizado duplo-cego de intervenção. Foram recrutados idosos não institucionalizados que apresentaram de um a dois critérios de fragilidade biológica. Os idosos foram distribuídos em dois grupos: um recebeu glutamina(GLU) e outro maltodextrina, utilizado como placebo(PLA) durante seis meses, em duas doses diárias. No início e ao fmal do estudo os indivíduos foram avaliados pelo peso e estatura, para cálculo do índice de massa corporal(IMC), circunferências da cintura, quadril, panturrilha e braço(CC,CQ,CP e CB) e dobra cutânea tricipital(DCT); composição corporal porbioimpedância elétrica, observando os valores de resistência(R), reactância(Xc), ângulo de fase(AF), água extra e intracelular e capacitância; força de preensão palmar(FPM); concentração sérica de citocinas (IL-IO, IL-6 e TNF-α); concentração sérica de creatinina e ureia para avaliação de função renal, por meio do cálculo da depuração de creatinina(Cockcorft&Galt); ingestão alimentar pelo recordatório alimentar de 24 horas e diário alimentar; nível de atividade fisica pelo questionário de Baecke; funcionamento intestinal pela escala de Bristol. Resultados-Foram incluídos no estudo 49 idosos, divididos 25 no GLU e 24 no PLA. Embora nenhuma das variáveis tenha apontado diferença significativa na comparação relacionada ao tempo (antes e depois da suplementação) e ao tratamento (glutamina ou placebo), a evolução de algumas variáveis indicou vantagens para o GLU, a saber: maiores valores de FPM; maiores valores do IMC, ligeiro aumento da CB e ligeira diminuição da DCT, menores variações das outras medidas corporais; valores de Xc, AF e água intracelular mostraram um melhor estado celular no GLU. Conclusões-A suplementação com glutamina em idosos em risco de fragilidade mostrou variações que podem ser interpretadas como possíveis beneficios ao funcionamento intestinal e à composição corporal. Dada a grande variabilidade dos resultados, não foi possível estabelecer diferenças estatísticas que pudessem confirmar essas variações. Estudos com amostras maiores, e com medidas prévias da permeabilidade intestinal, podem esclarecer os achados. / Introduction-Having in mind the role of glutamine as an energy substrate to enterocytes, as well as a nitrogen reserve to skeletal muscle, the study hypothesized that glutamine supplementation is capable of modulating the systemic inflammation and improving muscle mass as consequence. Objectives-to evaluate the effects of glutamine supplementation on some inflammatory markers and on the body composition of elderly in risk of frailty. Methods-randomized double-blind clinicai trial (RCT). This study included community-dwelling elderly (above 65 years old), who presented one or two criteria to develop frailty syndrome. The elderly were distributed in two groups, one of them received glutamine (GLU) and the other received placebo (PLA; maltodextrin) for 6 months, in two daily doses. In beginning and cnd of the experiment, the participants were evaluated for body weight and body height, to calculate the body mass index(BMI); waist, hip, calf and arm circumferences(WC,HC,CC,AC); tricipital skin folder(TSF); body composition by bioelectrical impedance measuring resistance, reactance, capacitance, phase angle, extra and intracellular water; grip strength; serum levei of inflammatory cytokines(IL-l0, IL-6 e TNF-α); serum creatinine and urea with evaluation ofkidney function by Cockcroft & Galt equation; food intake by a 24h food record; physical activity level by Baecke questionnaire; bowel function by Bristol scale. Results-49 participants were recruited, and distributed to both groups (GLU= 24 and PLA=24). Although none of the variables showed significant statistical differences, comparing together time (before and after) and group (glutamine or placebo), but evoluation of variables to demonstrate advantages to GLU supplementation, such as: higher grip strength values; higher values of BMI, slight enhance of AC and slight reduction in TSF, lower variation in anthropometric measures; BIA results showed better cellular conditions in GLU group (from reactance, phase angle and intracellular water). Conclusions - According to our experimental conditions, the glutamine supplementation in elderly at frailty risk showed some variability which could be interpreted as benefits either to body composition and gut function. However, due to the high variability presented in the results, it was not possible to find statistical significances, to confirm those finds. Studies involving a larger sample size, and preferably with measures of intestinal permeability, could clarify our results.

Introdução- Considerando o papel da glutamina como substrato energético para os enterácitos e como fornecedora de nitrogênio para o músculo esquelético, o estudo hipotetiza que a suplementação com glutamina pode contribuir na modulação da inflamação sistêmica e na preservação da massa muscular de idosos. Objetivos-avaliar os efeitos da suplementação com glutamina em alguns marcadores de inflamação e de composição corporal de idosos em risco de fragilidade. Métodos-estudo randomizado duplo-cego de intervenção. Foram recrutados idosos não institucionalizados que apresentaram de um a dois critérios de fragilidade biológica. Os idosos foram distribuídos em dois grupos: um recebeu glutamina(GLU) e outro maltodextrina, utilizado como placebo(PLA) durante seis meses, em duas doses diárias. No início e ao fmal do estudo os indivíduos foram avaliados pelo peso e estatura, para cálculo do índice de massa corporal(IMC), circunferências da cintura, quadril, panturrilha e braço(CC,CQ,CP e CB) e dobra cutânea tricipital(DCT); composição corporal porbioimpedância elétrica, observando os valores de resistência(R), reactância(Xc), ângulo de fase(AF), água extra e intracelular e capacitância; força de preensão palmar(FPM); concentração sérica de citocinas (IL-IO, IL-6 e TNF-α); concentração sérica de creatinina e ureia para avaliação de função renal, por meio do cálculo da depuração de creatinina(Cockcorft&Galt); ingestão alimentar pelo recordatório alimentar de 24 horas e diário alimentar; nível de atividade fisica pelo questionário de Baecke; funcionamento intestinal pela escala de Bristol. Resultados-Foram incluídos no estudo 49 idosos, divididos 25 no GLU e 24 no PLA. Embora nenhuma das variáveis tenha apontado diferença significativa na comparação relacionada ao tempo (antes e depois da suplementação) e ao tratamento (glutamina ou placebo), a evolução de algumas variáveis indicou vantagens para o GLU, a saber: maiores valores de FPM; maiores valores do IMC, ligeiro aumento da CB e ligeira diminuição da DCT, menores variações das outras medidas corporais; valores de Xc, AF e água intracelular mostraram um melhor estado celular no GLU. Conclusões-A suplementação com glutamina em idosos em risco de fragilidade mostrou variações que podem ser interpretadas como possíveis beneficios ao funcionamento intestinal e à composição corporal. Dada a grande variabilidade dos resultados, não foi possível estabelecer diferenças estatísticas que pudessem confirmar essas variações. Estudos com amostras maiores, e com medidas prévias da permeabilidade intestinal, podem esclarecer os achados. / Introduction-Having in mind the role of glutamine as an energy substrate to enterocytes, as well as a nitrogen reserve to skeletal muscle, the study hypothesized that glutamine supplementation is capable of modulating the systemic inflammation and improving muscle mass as consequence. Objectives-to evaluate the effects of glutamine supplementation on some inflammatory markers and on the body composition of elderly in risk of frailty. Methods-randomized double-blind clinicai trial (RCT). This study included community-dwelling elderly (above 65 years old), who presented one or two criteria to develop frailty syndrome. The elderly were distributed in two groups, one of them received glutamine (GLU) and the other received placebo (PLA; maltodextrin) for 6 months, in two daily doses. In beginning and cnd of the experiment, the participants were evaluated for body weight and body height, to calculate the body mass index(BMI); waist, hip, calf and arm circumferences(WC,HC,CC,AC); tricipital skin folder(TSF); body composition by bioelectrical impedance measuring resistance, reactance, capacitance, phase angle, extra and intracellular water; grip strength; serum levei of inflammatory cytokines(IL-l0, IL-6 e TNF-α); serum creatinine and urea with evaluation ofkidney function by Cockcroft & Galt equation; food intake by a 24h food record; physical activity level by Baecke questionnaire; bowel function by Bristol scale. Results-49 participants were recruited, and distributed to both groups (GLU= 24 and PLA=24). Although none of the variables showed significant statistical differences, comparing together time (before and after) and group (glutamine or placebo), but evoluation of variables to demonstrate advantages to GLU supplementation, such as: higher grip strength values; higher values of BMI, slight enhance of AC and slight reduction in TSF, lower variation in anthropometric measures; BIA results showed better cellular conditions in GLU group (from reactance, phase angle and intracellular water). Conclusions - According to our experimental conditions, the glutamine supplementation in elderly at frailty risk showed some variability which could be interpreted as benefits either to body composition and gut function. However, due to the high variability presented in the results, it was not possible to find statistical significances, to confirm those finds. Studies involving a larger sample size, and preferably with measures of intestinal permeability, could clarify our results.

Major depressive disorder (MDD) is rapidly growing and one of the most common causes of disability and mortality worldwide. People with MDD often display brain changes such as adisrupted balance in neurotransmitters, impaired neurogenesis and neuroplasticity. Traditionally has MDD been treated with medications and talking therapies (psychotherapy). Studies have shown that just around 50 % of people with MDD get improvements from common traditional treatments.Therefore is there a great need for a better understanding of MDD and new treatments. There is now an emerging field of research that indicates that the gut microbiota plays a crucial role in disturbing normal brain functioning in MDD. This connection between the gut and the brain is called the gutbrain axis.The thesis aims to investigate if there is a connection between gut microbiota disruption and MDD and if gut microbiota restoration can be a potential effective future treatment for MDD. Key findings of the thesis were, studies show that people with MDD often display gut microbiota disruption and chronic low grade inflammation. Studies also indicate that this inflammation can cause the specific brain change often displayed in people with MDD. One of the most critical findings in the thesis was that gut brain treatments affect tryptophan metabolism, which affects the risk of MDD. The research area of the gut brain axis is still new and many more studies are needed,particularly in humans.

Background Osteoarthritis (OA) is a long-term chronic disease that affects the joints and creates stiffness, pain and impaired movement. Knee osteoarthritis is the most common form of OA and affects all tissues of the joint, including bone, muscles, synovia, and cartilage. Previously, OA was accepted as only an age- or mechanical stress-related degenerative joint disease, but more recent studies suggest that OA is a heterogenous disease including inflammatory, hormonal and metabolic factors such as abdominal obesity (visceral fat), lipids (cholesterol, HDL, LDL and triglycerides) and glucose.    Aim The aim was to investigate the association of metabolic factors including fasting blood glucose, HbA1c, triglycerides, cholesterol, LDL, HDL, visceral fat, CRP and radiographic KOA in patients with symptomatic knee osteoarthritis. Methods Data were acquired from 91patients in the ages 30 – 63 experiencing symptomatic knee osteoarthritis. All subjects where divided into two groups depending on their level of fasting glucose, high versus low. Group I (n=26) had high glucose levels ≥5,6 mg/L and group II (n=65) had low glucose levels <5,6 mg/L.  Levels of HbA1c, lipids, visceral fat, CRP and radiographic KOA were then compared between the groups. Levels of fasting glucose, HbA1c and lipids (triglycerides, cholesterol, LDL, HDL) were analyzed by an accredited laboratory at the hospital of Halmstad by the department for labmedicine. CRP levels < 1 mg/L were manually analyzed with the sandwich ELISA method (enzyme-linked immunosorbent assay), which measures high-sensitive CRP (hsCRP) in serum. Visceral fat area was measured through bioelectrical impedance analysis (BIA) with InBody 770 and radiographs of the knees to obtain information about OA. Results There was a significant difference between the two groups in HbA1c, triglycerides, cholesterol and LDL p<0,05. Group I with high fasting glucose levels showed higher significant values of HbA1c, triglycerides, cholesterol and LDL than group II with low fasting glucose levels. 23% of all subjects met the requirement for metabolic syndrome according to IDF. Conclusion The findings in this study is in line with previous research and suggest that high glucose levels are associated with elevation of other metabolic factors in patients with knee osteoarthritis. However, there are several other interacting factors beyond the scope of this study, which may explain causalities. According to the findings in this study and previous research, obesity and metabolic syndrome could explain some of the connections between metabolic factors and knee osteoarthritis. Thus, further research is necessary to understand how all these metabolic factors are associated with osteoarthritis and obtain deeper knowledge about the pathogenesis and pathophysiology of the disease. / Detection and prediction of disease course in symptomatic knee osteoarthritis

Abstract Alopecia has been suggested to be associated with coronary artery diseases (CAD). However, the mechanism underlying this association has remained unclear. The purpose of the present study was to examine the relationships between metabolic syndrome-related risk factors, cardiovascular diseases (CVD) and alopecia among Finnish population. In addition, health-related quality of life (HRQOL) was studied in respect of alopecia among both genders. The data come from the national Finrisk survey alopecia sub-study (4 066 men aged 25–74 years old) and two community samples of men and women (aged 55 and 63 years) living in the city of Oulu in 2001 and 1998, respectively. The degree of alopecia was assessed using the Norwood-Hamilton classification scale for men and the Ludwig scale for women. This study showed a high prevalence of alopecia in the general male Finnish population varying from 17% to 73% among men aged 25–74 years, and its association with CVD particularly in age-groups older than 55 years. In addition, insulin resistance, as a metabolic syndrome-related risk factor, was associated with alopecia in middle-aged men. Among men younger than 35 years, low-grade inflammation was associated with alopecia, especially combined with central obesity. Further, in middle-aged general Finnish population, obesity associated most closely with low-grade inflammation, which is in line with the findings among young men with alopecia. Compared to subjects with no alopecia, HRQOL dimension scores (RAND-36) were significantly lower in physical functioning, role limitations due to physical health and general health among women with alopecia, and in physical functioning and social functioning among men with alopecia. Regression analyses of HRQOL-related factors revealed that alopecia was associated with role limitations due to physical health in women but not in men. An association between alopecia and CVD was strengthened in this study. In addition, low-grade inflammation and insulin resistance were associated with alopecia, especially with early onset alopecia. In elderly women, alopecia seemed to be associated with morbidity in vascular diseases. In the future, recognition of the risk factors for cardiovascular disease among subjects with alopecia is a challenge for primary health care that may prevent the development of arterial diseases. / Tiivistelmä Hiustenlähdön yhteys sydän- ja verisuonisairauksiin on ollut tiedossa jo pitkään, mutta yhteyden taustalla olevat patofysiologiset mekanismit ovat edelleenkin epäselviä. Tässä väitöskirjatyössä tutkittiin hiustenlähdön yhteyksiä metaboliseen oireyhtymään ja siihen liittyviin riskitekijöihin suomalaisessa väestössä yleisesti. Lisäksi tutkittiin elämänlaadun yhteyttä hiustenlähtöön 63-vuotiailla miehillä ja naisilla. Tutkimukseen käytettiin kolmea aineistoa; kansallisen Finrisk 2002 tutkimuksen alopecia (hiustenlähtö) alaotos (4066 iältään 25–74-vuotiasta miestä) ja kaksi aineistoa Oulun kaupungista (Oulussa asuneet 55- ja 63-vuotiaat miehet ja naiset vuonna 2001 ja 1998). Hiustenlähdön laajuus määriteltiin miehillä Norwood-Hamiltonin ja naisilla Ludwigin luokitteluasteikon mukaan. Hiustenlähdön esiintyvyys suomalaisessa miesväestössä vaihteli 17 %:sta (25–34-vuotiaat) 73 %:iin (65–74-vuotiaat) ja se näytti liittyvän sydän- ja verisuonisairauksiin 55-vuotiailla ja sitä vanhemmilla miehillä. Lisäksi alentunut insuliiniherkkyys metabolisen oireyhtymän merkkinä oli yhteydessä hiustenlähtöön keski-ikäisillä miehillä. Varhain alkanut hiustenlähtö (alle 35-vuotiaat) liittyi matala-asteiseen tulehdukseen erityisesti keskivartalolihavilla kaljuuntuvilla nuorilla miehillä. Samansuuntainen tulos tuli esille myös väestötutkimuksessa 55-vuotiailla oululaisilla miehillä ja naisilla, jonka mukaan matala-asteinen tulehdus oli yhteydessä erityisesti yleiseen lihavuuteen eikä pelkästään vyötärölihavuuteen. Terveyteen liittyvän elämänlaadun osa-alueiden pisteet (RAND-36) 63-vuotialla hiustenlähdöstä kärsivillä naisilla olivat merkittävästi matalampia kolmella osa-alueella; fyysiset toiminnot, fyysisen terveydentilan aiheuttamat muutokset roolitoiminnoissa ja yleinen terveys. Samanikäisillä kaljuuntuvilla miehillä merkittävästi matalammat terveyteen liittyvät elämänlaadun osakomponentit olivat fyysisten ja sosiaalisten toimintojen alueella. Tilastollisessa regressioanalyysissä ilmeni, että hiustenlähtö selitti fyysisen terveydentilan aiheuttamia rajoituksia roolitoimintoihin erityisesti kaljuuntuvilla naisilla, mutta ei miehillä. Hiustenlähdön yhteys eri sydän- ja verisuonisairauksiin vahvistui tässä tutkimuksessa. Varhainen hiustenlähtö on ilmeisesti merkki sekä matala-asteisesta tulehduksesta että alentuneesta insuliiniherkkyydestä. Myös naisilla hiustenlähtö näyttäisi liittyvän suurempaan sairastavuuteen. Terveydenhuollon tulisi jatkossa tarkemmin paneutua sydän- ja verisuonisairauksien riskin kartoittamiseen hiustenlähdöstä kärsivien potilaiden kohdalla.

Abstract Cardiovascular diseases (CVD), and especially atherosclerotic vascular diseases (ASVD), are the largest cause of morbidity and premature death worldwide. Coronary heart disease (CHD) and cerebrovascular disease (stroke) are common and severe manifestations of ASVD. Atherosclerosis is a chronic inflammatory disease and lipoprotein metabolism disorder. If the regulation of inflammatory process is disturbed, the systemic release of pro-inflammatory mediators, including matrix metalloproteinases (MMPs), may lead to a low-grade systemic inflammation, which is a risk factor for CVDs. MMPs are enzymes that are responsible for the degradation of the extracellular matrix (ECM) during growth and tissue renewal but also in many pathological conditions. These ECM degrading proteases and their regulators play an important role in atherogenesis and subsequent plaque rupture, leading to acute cardiovascular manifestations. The pivotal role of MMPs in atherosclerosis has raised interest in the development of drug therapies targeting these proteases. Doxycycline has inhibitory effects on some MMPs in addition to its antimicrobial properties. The main objective of this thesis project was to investigate the potential of these inflammatory mediators as biomarkers, risk factors, and therapeutic targets in CVD. The special focus was on MMP-8 and its main regulator, tissue inhibitor of matrix metalloproteinase (TIMP)-1. The results of this study show that a high serum MMP-8 concentration indicates an acute cardiac condition and predicts a future CVD event. In addition to MMP-8, MMP-7 is a potential biomarker for incident CVD. The balance between these MMPs and their tissue inhibitor may indicate vulnerability to plaque rupture. Measurement of serum MMP-8 concentration is reliable, anti-invasive and inexpensive and can be done in hospital settings. We also show that regular-dose doxycycline decreases the systemic inflammatory burden in patients with earlier myocardial infarction and is a promising anti-inflammatory therapy in the prevention of CVDs with relatively minor side effects. In conclusion, MMP-8 and TIMP-1 can be considered inflammatory risk markers of CVD events and death, and they can be utilized both for diagnostic and screening purposes. The inhibition of MMP-8 by doxycycline may reduce the systemic inflammatory burden in patients with myocardial infarction. / Tiivistelmä Sydän- ja verisuonisairaudet, erityisesti ateroskleroottiset valtimosairaudet, ovat maailman yleisin sairastuvuuden ja ennenaikaisen kuoleman syy. Sepelvaltimotauti ja aivohaveri ovat ateroskleroottisen valtimosairauden yleisiä ja vakavia ilmenemismuotoja. Ateroskleroosi on krooninen tulehduksellinen sairaus ja lipoproteiiniaineenvaihdunnan häiriö. Jos tulehdustapahtuma häiriintyy, elimistöön vapautuvat tulehdusvälittäjäaineet, kuten matriksin metalloproteinaasit (MMP), voivat aiheuttaa elimistön matala-asteisen tulehduksen, joka on sydän- ja verisuonisairauksien riskitekijä. MMP:t ovat entsyymejä, jotka pilkkovat solunväliainetta kasvun ja kudosten uusiutumisen mutta myös monien tautitilojen yhteydessä. Nämä soluväliainetta hajottavat proteaasit ja niiden säätelijät ovat tärkeässä roolissa ateroskleroottisen plakin muodostumisessa ja repeämisessä, joka johtaa äkillisiin sydäntautitapahtumiin. Matriksin metalloproteinaasien keskeinen rooli ateroskleroosissa on herättänyt kiinnostusta niihin kohdistuvan lääkehoidon kehittämiseen. Doksisykliinillä on joidenkin MMP-entsyymien toimintaa estävä vaikutus antimikrobiaalisten ominaisuuksiensa lisäksi. Tämän väitöskirjatutkimuksen päätavoitteena oli tutkia näiden tulehdusvälittäjäaineiden mahdollisuuksia biomarkkereina, riskitekijöinä ja lääkehoidon kohteena sydän- ja verisuonisairauksissa. Erityinen kiinnostuksen kohde oli MMP-8 ja sen pääsäätelijä ja kudosestäjä, tissue inhibitor of matrix metalloproteinase (TIMP)-1. Tämän tutkimuksen tulokset osoittavat, että seerumin korkea MMP 8 pitoisuus viittaa akuuttiin sydäntautiin ja ennakoi tulevaa sydäntautitapahtumaa. MMP-8:n lisäksi MMP-7 on lupaava sydäntapahtuman biomarkkeri. Näiden matriksin metalloproteinaasien ja niiden kudossäätelijä TIMP-1:n välinen tasapaino voi liittyä ateroskleroottisen plakin haurauteen. Seerumin MMP-8:n mittaus on luotettavaa, kajoamatonta ja edullista, ja mahdollista toteuttaa myös sairaalaolosuhteissa. Näytämme myös, että doksisykliini vähentää elimistön tulehdustaakkaa sydäninfarktin sairastaneilla potilailla ja että se on sydäntautien ehkäisyssä lupaava anti-inflammatorinen lääke, jolla on suhteellisen vähän sivuvaikutuksia. Johtopäätöksenä on, että MMP-8:aa ja TIMP-1:tä voidaan pitää lupaavina sydän- ja verisuonitautien sekä kuoleman biomarkkereina sekä diagnostiikka- että seulontakäytössä. Lisäksi tutkimustulokset osoittavat, että MMP-8:n esto doksisykliinillä voi vähentää elimistön tulehdustaakkaa sydänkohtauksen sairastaneilla potilailla.

Les cytokines, produites lors de l’activation du système immunitaire, ont la capacité d’agir au niveau du système nerveux central et d’induire diverses altérations comportementales. Lorsque l’activation du système de l’immunité innée devient chronique, ces altérations comportementales peuvent évoluer en véritables symptômes neuropsychiatriques. La physiopathologie des symptômes neuropsychiatriques qui se développent dans un contexte d’inflammation chronique à bas bruit, c’est-à-dire caractérisé par une activation chronique des processus immunitaires mais à un niveau relativement faible, est peu connue et reste à déterminer. L’implication de l’inflammation chronique à bas bruit dans les symptômes de fatigue et les altérations cognitives constitue l’élément d’étude principal de ce travail de thèse. Les troubles métaboliques, tels que l’obésité et le diabète de type 2, sont de bons modèles pour une telle étude. Ces deux pathologies sont en effet caractérisées par une inflammation chronique à bas bruit qui proviendrait, au moins en partie, du tissu adipeux. De plus, la fatigue et les altérations cognitives sont fréquentes chez les patients souffrant de troubles métaboliques. Compte tenu du rôle connu de l’inflammation dans la physiopathologie de ces altérations comportementales, leur développement dans des contextes de troubles métaboliques pourrait également être lié à l’activation chronique à bas bruit de processus inflammatoires. Différents objectifs ont été définis pour tester cette hypothèse : 1) caractériser et spécifier les symptômes de fatigue et les altérations cognitives chez des patients diabétiques ou obèses ; 2) évaluer la relation entre inflammation systémique et état inflammatoire du tissu adipeux ; 3) étudier l’association de l’inflammation chronique à bas bruit avec les symptômes de fatigue et les altérations cognitives des patients souffrant de troubles métaboliques. Nos résultats indiquent que la fatigue, en particulier la fatigue générale et physique, représente une caractéristique fondamentale des troubles métaboliques. Des perturbations cognitives, se traduisant par un ralentissement psychomoteur dans un test de temps de réaction ainsi qu’une altération de performance dans une tâche de planification spatiale, ont également été décelées chez les patients diabétiques de type 2, particulièrement ceux sous insulinothérapie, et chez les patients obèses. Des altérations mineures étaient également mesurées dans une tâche d’empan spatial rétrograde chez les patients obèses. En ce qui concerne les données biologiques, nos résultats indiquent diverses associations entre l’inflammation systémique et l’expression des marqueurs inflammatoires (cytokines inflammatoires, dont le MCP1, et marqueurs des cellules T) dans le tissu adipeux viscéral des patients obèses. De façon intéressante, l’inflammation systémique à bas bruit était associée aux dimensions de fatigue (générale, mentale, réduction des activités et de la motivation) et aux altérations de performance dans les tests ciblant les fonctions exécutives. Dans l’ensemble, ces résultats supportent l’hypothèse de l’implication des macrophages et des lymphocytes T du tissu adipeux dans l’état inflammatoire systémique associé à l’obésité. Il suggère en outre que l’inflammation systémique à bas bruit pourrait participer au développement de la fatigue et des altérations cognitives chez les patients souffrant de troubles métaboliques. Ce travail de thèse offre une caractérisation précise des symptômes de fatigue et des altérations cognitives associées aux troubles métaboliques. En outre, ce travail apporte d’importantes informations sur les relations de l’inflammation chronique à bas bruit avec ces symptômes, et permet d’affiner les hypothèses relatives à l’implication de processus inflammatoires dans la physiopathologie de ces altérations. / Cytokines produced during the activation of the immune system have the ability to act within the central nervous system and to induce a large number of behavioral alterations. When the activation of immune system becomes chronic and unregulated, these behavioral alterations may lead to the development of neuropsychiatric symptoms. The pathophysiology of neuropsychiatric symptoms that develop in conditions of chronic low-grade inflammation context (i.e., characterized by a chronic but low activation of inflammatory processes), remains unknown. The main aim of this thesis was to investigate the involvement of low-grade inflammation in the development of fatigue symptoms and cognitive alterations in patients with metabolic disorders including obesity and type 2 diabetes. These conditions are characterized by a chronic low-grade inflammatory state, manifesting by higher blood concentrations of inflammatory factors. This inflammatory state would originate, at least partially, from the adipose tissue. Moreover, fatigue symptoms and cognitive alterations are common in metabolic disorders. Given the role of inflammation in the physiopathology of these symptoms, their development could also rely on chronic low-grade inflammatory processes. Several objectives were defined to test this hypothesis: 1) to characterize fatigue symptoms and cognitive alterations in obese and diabetic patients; 2) to assess the relationship of systemic inflammation with the inflammatory state of the adipose tissue; and 3) to investigate the association of low-grade inflammation with fatigue symptoms and cognitive alterations in patients with metabolic disorders. Fatigue symptoms and cognitive function were respectively assessed using the multidimensional fatigue inventory (MFI) and the neuropsychological tests automated battery CANTAB in diabetic patients (type 1 and type 2) and in obese patients before and after bariatric surgery. A control group was included for each model (obesity and type 2 diabetes). Circulating concentrations of inflammatory markers, as well as expression of inflammatory markers in the visceral adipose tissue of obese patients, were measured. Our results indicate that fatigue symptoms, especially in the dimensions of general and physical fatigue, represent fundamental characteristics of patients suffering from metabolic disorders. In addition, cognitive alterations (psychomotor slowing and alterations in spatial planning performance) were measured in type 2 diabetic patients, more particularly those under insulin treatment, and in obese patients. Slight alterations in the test of backward spatial span were measured in obese patients. With respect to biological data, our results indicate significant relationships between systemic inflammation and inflammatory markers (inflammatory cytokines, including MCP1, and T-cell markers) in the visceral adipose tissue of obese patients. Interestingly, chronic low-grade inflammation was associated with fatigue symptoms (general fatigue, mental fatigue, reduced activity and motivation) and performance alterations in tests assessing executive functions. Altogether, these data support the hypothesis of the involvement of the adipose macrophages and T lymphocytes in the systemic inflammatory state associated with obesity. Moreover, these results suggest that systemic low-grade inflammation associated with metabolic disorders may contribute to the physiopathology of fatigue and cognitive alterations in these conditions. In conclusion, these studies provide a precise characterization of fatigue symptoms and cognitive alterations associated with metabolic disorders, such as obesity or type 2 diabetes. In addition, this thesis work gives interesting information about the relationships of chronic low-grade inflammation and fatigue and cognitive symptoms, and refines hypotheses regarding the involvement of inflammatory processes in the physiopathology of these symptoms in patients with diabetes or obesity.

Abstract Skin diseases are common: one in every three of all general practice patients have at least one dermatological problem. However, epidemiological studies addressing the overall prevalence of skin diseases are sparse. The skin is the largest organ in the body and it has several vital and immunological functions. Cutaneous signs are often the first manifestation of many systemic diseases. The aim of this study was to determine the overall prevalence, and the distribution according to sex and socioeconomic status, of skin diseases in an adult population. The study particularly focused on multiple melanocytic naevi and their risk factors because multiple melanocytic naevi are the strongest risk factor for melanoma. A further aim was to analyse the association between cutaneous disorders and systemic conditions; specifically to determine whether abnormal skin findings in toe webs have an association with abnormal glucose metabolism and whether skin diseases have a relationship with systemic low-grade inflammation. For these purposes a comprehensive dermatological evaluation was performed as a part of the 46-year follow-up survey of the Northern Finland Birth Cohort 1966. Data on this cohort have been collected since birth. Numerous laboratory tests were also performed cross-sectionally during the 46-year follow-up survey, including an oral glucose tolerance test and the measurement of fasting plasma glucose and glycated haemoglobin fraction. High sensitivity C-reactive protein was measured as a marker of low-grade inflammation. Over half (60%) of the 1 932 individuals examined had at least one skin disorder requiring further treatment. The need for treatment was more common in males and those with lower socioeconomic status. Multiple melanocytic naevi were found in 12% of individuals; high educational level, male sex and fair skin type increased the risk. Abnormal skin findings in toe web spaces was associated with undiagnosed type 2 diabetes. Atopic eczema, rosacea and onychomycosis were associated with low-grade inflammation. This unique study with nearly 2 000 subjects reports for the first time the overall prevalence of skin diseases in an unselected Finnish population. Its findings support the previous postulate that skin diseases are common in adults and suggest that skin evaluation should be an essential part of routine medical examinations in clinical practice. / Tiivistelmä Ihotaudit ovat yleisiä, ja jopa 30 %:lla yleislääkärin potilaista on jokin ihoon liittyvä ongelma. Väestötason tutkimuksia ihotaudeista on kuitenkin niukasti. Iho on ihmisen suuri elin, ja sillä on useita tärkeitä tehtäviä, kuten osallistuminen immunologiseen puolustukseen. Monet yleissairaudet voivat näkyä iholla jo ennen taudin puhkeamista ja ihoilmentymät voivat olla varhaisia merkkejä piilevästä sairaudesta. Tämän tutkimuksen tarkoituksena oli määrittää ihotautien esiintyvyys aikuisväestössä sekä ihotautien jakautuminen sukupuolen ja sosiaalisen aseman suhteen. Lisäksi tarkoituksena oli selvittää runsasluomisuuden (yli 50 pigmenttiluomea) esiintyvyyttä ja sen riskitekijöitä, sillä runsasluomisuus on melanooman merkittävin riskitekijä. Tutkimuksen tavoitteena oli myös selvittää ihotautien yhteyttä yleissairauksiin, kuten poikkeavien varvasvälilöydösten yhteyttä häiriintyneeseen sokeriaineenvaihduntaan sekä matala-asteisen tulehduksen ja ihotautien välistä yhteyttä. Osana Pohjois-Suomen syntymäkohortti 1966:n 46-vuotistarkastusta tehtiin kokonaisvaltainen ihon tutkiminen yhteensä 1 932:lle tutkimushenkilölle vuosina 2012–13. Samassa yhteydessä tutkittavilta määritettiin paastoverensokeri ja pitkäaikainen verensokeri sekä tehtiin sokerirasitustesti sokeriaineenvaihdunnan häiriön toteamiseksi. Matala-asteisen tulehduksen arvioimiseksi määritettiin herkkä C-reaktiivinen proteiini. Tutkimusjoukon pitkäaikaiset taustatiedot perustuivat syntymäkohortin aiempiin aineistoihin. Tutkittavista 60 %:lla todettiin jokin hoitoa vaativa ihotauti. Hoidon tarve oli suurempaa miehillä ja matalammissa sosiaaliluokissa. Runsasluomisuutta esiintyi 12 %:lla, ja korkea koulutustaso, miessukupuoli ja vaalea ihotyyppi lisäsivät riskiä. Varvasväleissä esiintyvät muutokset liittyivät diagnosoimattomaan diabetekseen. Atooppinen ihottuma, ruusufinni ja kynsien sieni-infektioon sopivat muutokset olivat yhteydessä matala-asteiseen tulehdukseen. Tämä lähes 2 000 henkilön koko ihon kliiniseen tutkimukseen perustuva työ raportoi ensimmäistä kertaa ihotautien yleistä esiintyvyyttä suomalaisessa, valikoitumattomassa väestössä. Tutkimus tukee aiempaa oletusta, jonka mukaan ihotaudit ovat aikuisväestössä yleisiä; ihon tutkiminen tulisi olla oleellinen osa potilaan kliinistä perustutkimusta.

Abstract Depression, anxiety and sleep disorders have been reported to be associated with low level of inflammation, i.e., low-grade inflammation, but mainly in males. The evidence has mainly been based on laboratory or clinical studies with small sample sizes or epidemiological studies with elderly subpopulations. In this study the association of low-grade inflammation with depression, anxiety, and sleep disturbances was investigated using the Northern Finland 1966 Birth Cohort (NFBC 1966). In women, the effect of hormonal factors, menopause and the use of oral contraceptives/hormone replacement therapy on the association between low-grade inflammation and depression was also studied by using the Pieksämäki Study data. In 31-year follow-up of NFBC 1966 (N=6007), the depressive and anxiety symptoms were assessed by Hopkins Symptom Checklist-25 (HSCL-25) and sleep disorders by 15-D questionnaires, while the marker of low-grade inflammation, plasma concentration of high sensitivity C-reactive protein (hs-CRP), was measured. In the Pieksämäki study a representative sample of inhabitants in the town of Pieksämäki were invited to clinical examination. Depressive symptoms were obtained by Beck’s Depression Inventory-21, and hs-CRP was measured (512 women). The results of this study revealed that at epidemiological level, elevated hs CRP levels of ≥1.0 mg/L increased the probability of current depressive symptoms of single depressive episode in the two highest subgroups (i.e., HSCL-25 mean scores ≥1.75 and ≥2.01) 1.4- and 1.7- fold in males, respectively. In addition, anxiety symptoms (HSCL-25 anxiety scale mean score ≥1.75) increased independently the probability of elevated hs-CRP levels (>3.0 mg/L) in males over 2-fold. Risk ratio of 1.3 was found for males with moderate to severe sleep disturbances and elevated hs-CRP levels (≥1.0 mg/L). Regarding females, a positive correlation between elevated hs-CRP levels and depressive symptoms was found only among peri- and postmenopausal women not using exogenous hormones. The results suggest that low-grade inflammation is associated not only with depression but also with anxiety and sleep disturbances in young adult men. In women, hormonal factors may have an effect on the association between low-grade inflammation and depression. Further investigations are called for to confirm these findings and furthermore, to determine the possible role of low-grade inflammation in the pathophysiology of these disorders. / Tiivistelmä Depressio, ahdistuneisuushäiriöt ja unihäiriöt on yhdistetty elimistön matala-asteiseen tulehdustilaan, joskin pääasiallisesti vain miehillä. Tulosten yleistettävyyttä ovat rajoittaneet tutkimusten pienet otoskoot tai painottuminen iäkkäisiin väestöaineistoihin. Tässä tutkimuksessa selvitettiin matala-asteisen tulehduksen yhteyttä depressioon, ahdistuneisuuteen ja unihäiriöihin Pohjois-Suomen syntymäkohortti 1966 -aineistossa. Lisäksi Pieksämäki-tutkimuksen aineistossa selvitettiin naisilla menopaussin ja ehkäisyvalmisteiden/vaihdevuosihormonikorvaushoidon vaikutusta depression ja matala-asteisen tulehduksen väliseen yhteyteen. Pohjois-Suomen syntymäkohortti 1966 -tutkimuksen 31-vuotisseurannassa kartoitettiin 6007 henkilöltä masennus- ja ahdistuneisuusoireita Hopkins Symptom Checklist-25 -arviointiasteikolla (HSCL-25) ja unihäiriöitä 15-D-kyselyllä. Lisäksi mitattiin matala-asteisen tulehduksen mittarina käytetyn herkän C-reaktiivisen proteiinin (CRP) pitoisuus. Pieksämäki-tutkimuksessa edustava otos Pieksämäen asukkaista kutsuttiin kliiniseen tutkimukseen ja depressiivisiä oireita kartoitettiin Beckin 21-osioisella arviointiasteikolla ja mitattiin herkkä CRP (512 naista). Nuorilla aikuisilla miehillä, joiden herkkä CRP oli kohonnut (≥1.0 mg/l), todettiin 1.7-kertainen masennusoireiden riski, kun katkaisupisteenä käytettiin HSCL-25-kyselyn masennuskeskiarvopistettä ≥2.01. Ahdistuneisuusoireet (HSCL-25-kyselyn ahdistuneisuuskeskiarvopisteet ≥1.75) lisäsivät kohonneen herkän CRP:n riskiä (>3.0 mg/l) yli kaksinkertaiseksi miehillä. Keskivaikeasta tai vaikeasta unihäiriöstä kärsivillä todettiin 1.3-kertainen kohonneen herkän CRP:n (≥1.0 mg/l) riski. Naisilla positiivinen yhteys masennuksen ja kohonneen herkän CRP:n välillä todettiin vain peri- ja postmenopausaalisilla naisilla, jotka eivät käyttäneet hormonikorvaushoitoa tai suun kautta otettavia ehkäisyvalmisteita. Tutkimustulokset viittaavat matala-asteisen tulehduksen liittyvän depressioon, ahdistukseen ja unihäiriöön nuorilla aikuisilla miehillä. Naisilla hormonaaliset seikat mahdollisesti vaikuttavat depression ja matala-asteisen tulehduksen väliseen yhteyteen. Tulevaisuuden tutkimushaasteena on selvittää matala-asteisen inflammaation mahdollinen merkitys depression, ahdistuneisuuden ja unihäiriöiden patofysiologiassa.